An Agent-Based Model of Combination Oncolytic Viral Therapy and Anti-PD-1 Immunotherapy Reveals the Importance of Spatial Location When Treating Glioblastoma
Oncolytic viral therapies and immunotherapies are of growing clinical interest due to their selectivity for tumor cells over healthy cells and their immunostimulatory properties. These treatment modalities provide promising alternatives to the standard of care, particularly for cancers with poor pro...
Guardado en:
Autores principales: | Kathleen M. Storey, Trachette L. Jackson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a382b4a66f94026b9897491d6da4ce9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Masmudur M. Rahman, et al.
Publicado: (2021) -
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
por: Rui Xing, et al.
Publicado: (2021) -
Multi-Omics Analysis of Glioblastoma Cells’ Sensitivity to Oncolytic Viruses
por: Anastasiya V. Lipatova, et al.
Publicado: (2021) -
Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
por: Mai F. Tolba, et al.
Publicado: (2021) -
Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice
por: Tan Y, et al.
Publicado: (2021)